Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Complete Spinal Cord Injury

We are developing an innovative treatment that aims to improve the patients’ quality of life.

Read more

Press releases

• December 14, 2018 - Regulatory press releaseBioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance
• November 13, 2018 - Other press releaseBioArctic to present at Jefferies 2018 London Healthcare Conference on November 15
• November 12, 2018 - Regulatory press releaseBioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s

Archive

Interim Report January – September 2018

BioArctic AB published the company’s Interim Report January – September 2018 on Thursday, November 8.

• Report
• Presentation
• Press release
• Webcast

Read the report

Calendar

• February 14, 2019Full Year Report 2018
• March 6, 2019Carnegie Nordic Healthcare Seminar in Stockholm, Sweden
• April 15, 2019 - April 18, 2019Annual Report 2018

All events